Is BPC-157 approved or legal?

No. BPC-157 is not approved as a drug by the FDA, EMA, or most regulators. The FDA has placed it on a list of substances ineligible for compounding, and it is banned in competitive sport by WADA. Products are typically sold for research use only, not for human consumption.

What dose and how often do people use, and what is the half-life?

There is no validated clinical dose. Community (anecdotal) protocols commonly cite ~250-500 mcg once or twice daily in 4-8 week cycles, often injected subcutaneously near an injury. Systemic half-life is very short (under ~30 minutes in animal studies), though reported effects appear to outlast plasma levels. This is reference information, not dosing advice.

Does BPC-157 actually work for healing injuries?

Preclinical (animal and cell) studies consistently suggest benefits for tendon, muscle, and gut healing, but human evidence is limited to a few small pilot studies. It is biologically plausible and widely reported anecdotally, but not proven effective in well-controlled human trials.

Oral capsules or injection?

Injectable forms have higher systemic bioavailability and are favored anecdotally for musculoskeletal goals, while oral/capsule forms are discussed mainly for gut-related goals on the rationale that the peptide acts locally in the digestive tract. Neither route has rigorous human efficacy data.

Short-term tolerability appears favorable in animals and the few small human reports, with no lethal dose identified in animal toxicology. However, long-term human safety is unstudied, a theoretical concern exists around promoting angiogenesis in the setting of cancer, and unregulated product quality is a real risk. It is not recommended for human use.

Recovery

BPC-157

Also known as: Body Protection Compound-157, PL 14736, Bepecin, PL-10

A synthetic gastric pentadecapeptide studied for tissue repair. Evidence is largely preclinical; human data is minimal. Research use only.

Last updated July 11, 2026

Reconstitute this peptide Buy BPC-157

Overview

BPC-157 is a synthetic peptide of 15 amino acids derived from a partial sequence of a protein found in human gastric juice. It is most commonly discussed in the context of musculoskeletal recovery, tendon and ligament healing, and gastrointestinal repair. Within research and fitness communities it is frequently grouped with TB-500 as a "recovery" peptide. The great majority of published BPC-157 research is preclinical, conducted in rodents and in vitro. These studies report effects on wound healing, angiogenesis, and gut protection. Human evidence remains scarce: only a handful of small, mostly unblinded pilot studies exist, with no large randomized placebo-controlled trials establishing efficacy or long-term safety as of 2026. BPC-157 is not an approved drug in the United States, the EU, or most jurisdictions. The FDA has flagged it as a substance not eligible for compounding, and it is prohibited in sport by WADA. Material sold online is typically labeled "for research use only," and the claims around it should be read with that regulatory and evidentiary context in mind. This entry summarizes the available science and community-reported practice for reference only. It is not medical advice and does not endorse human use.

How it works

BPC-157's proposed mechanism is not fully established, and most pathway data come from animal and cell models. The most consistently reported action is promotion of angiogenesis (new blood-vessel formation), apparently by upregulating VEGF and signaling through the VEGFR2-Akt-eNOS axis, which increases nitric oxide availability. It is also reported to modulate the nitric oxide (NO) system more broadly, influence ERK1/2 and FAK-paxillin signaling involved in fibroblast migration and tendon-cell outgrowth, and exert cytoprotective and anti-inflammatory effects on the gastrointestinal lining and other tissues. Some work suggests interaction with growth-hormone receptor expression and the dopaminergic and serotonergic systems via the gut-brain axis. Several effects follow a bell-shaped dose-response in animal models, meaning higher doses are not necessarily more effective. These mechanisms are plausible but should be considered provisional given the limited human validation.

Researched effects

Preclinical Accelerates tendon, ligament, and muscle healing after injury
Preclinical Protects and heals the gastrointestinal lining (ulcers, colitis, intestinal permeability)
Preclinical Promotes angiogenesis and improves blood flow to healing tissue
Preclinical Reduces inflammation and offers cytoprotection to multiple organs
Clinical Small pilot studies report symptom relief in knee pain and interstitial cystitis
Anecdotal Reduces joint pain and speeds recovery from soft-tissue injuries
Anecdotal Improves gut symptoms (IBS-like complaints, reflux) with oral use

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

No established or regulator-approved clinical dosing in humans. Published human data are limited to a few small pilot studies (e.g., localized bladder injection for interstitial cystitis; intra-articular/peri-articular injection for knee pain; a small IV tolerability report up to 20 mg). These are too small and heterogeneous to define a validated therapeutic dose, and no consensus clinical protocol exists.

Community-reported dosing (anecdotal)

Anecdotal and research-reference only; not medical advice or instruction. Community sources (including r/Peptides and peptide vendor guides) commonly describe reconstituted injectable protocols of roughly 250-500 mcg per dose, taken once or twice daily, often subcutaneously near the area of injury, in cycles of about 4-8 weeks followed by a break. Oral capsules are discussed mainly for gut-related goals on the rationale that the peptide acts locally on the GI tract. Some users cite the reported bell-shaped dose-response as a reason not to exceed these ranges. These figures reflect unverified community practice, not tested safe or effective doses.

Half-life: Very short systemically: animal pharmacokinetic data show an elimination half-life under ~30 minutes (~15 min in rats, ~5 min in dogs) after IV dosing, undetectable by ~4 hours. Despite this, biological effects are reported to outlast plasma presence (a PK-PD disconnect). Human half-life is not formally characterized.
Routes: subcutaneous, intramuscular, oral

Safety & side effects

Long-term human safety has not been established; there are no large or long-duration human trials. Preclinical toxicology and the few human reports describe a generally favorable short-term tolerability profile with no identified lethal dose in animals, and small human studies reported few adverse events. However, theoretical concerns remain, most notably that strong angiogenesis promotion could be undesirable in the presence of tumors or cancer risk; this has not been adequately studied. Community reports include injection-site reactions and, in some individuals, dizziness, vertigo, racing heart, headache, fatigue, brain fog, or anxiety/panic-like episodes after dosing. Product quality is a major real-world risk: research-grade material is unregulated and may be impure, mislabeled, or contaminated. BPC-157 is not FDA-approved, is excluded from FDA compounding, and is banned in competitive sport by WADA. This information is for research reference only and is not a recommendation for human use.

Research summary

The evidence base for BPC-157 is broad in scope but shallow in quality. A large number of preclinical papers, many from a small cluster of research groups, report consistent benefits across tendon, muscle, nerve, vascular, and gastrointestinal healing models, with angiogenesis via the VEGFR2-NO axis as a recurring mechanistic theme. Pharmacokinetic studies in rats and dogs confirm rapid systemic clearance, which makes the durable functional effects reported in tissue-healing models scientifically interesting but not fully explained. Human evidence is the critical gap. As of 2026 only a few small, mostly unblinded pilot studies have been published, collectively involving fewer than several dozen participants, and no adequately powered randomized placebo-controlled trial has confirmed efficacy. An earlier Phase I program was reportedly discontinued without published results. Consequently, claims of human benefit rest largely on extrapolation from animals plus anecdote. The honest assessment is that BPC-157 is a biologically plausible and promising recovery peptide in preclinical models, but it is unproven in humans, unapproved by regulators, and unstudied for long-term safety. Marketing language describing it as a guaranteed or miracle healing agent is not supported by the evidence. It should be treated as an experimental research compound, and the angiogenesis-cancer interaction question in particular warrants caution until studied.

FAQ

Is BPC-157 approved or legal?: No. BPC-157 is not approved as a drug by the FDA, EMA, or most regulators. The FDA has placed it on a list of substances ineligible for compounding, and it is banned in competitive sport by WADA. Products are typically sold for research use only, not for human consumption.
What dose and how often do people use, and what is the half-life?: There is no validated clinical dose. Community (anecdotal) protocols commonly cite ~250-500 mcg once or twice daily in 4-8 week cycles, often injected subcutaneously near an injury. Systemic half-life is very short (under ~30 minutes in animal studies), though reported effects appear to outlast plasma levels. This is reference information, not dosing advice.
Does BPC-157 actually work for healing injuries?: Preclinical (animal and cell) studies consistently suggest benefits for tendon, muscle, and gut healing, but human evidence is limited to a few small pilot studies. It is biologically plausible and widely reported anecdotally, but not proven effective in well-controlled human trials.
Oral capsules or injection?: Injectable forms have higher systemic bioavailability and are favored anecdotally for musculoskeletal goals, while oral/capsule forms are discussed mainly for gut-related goals on the rationale that the peptide acts locally in the digestive tract. Neither route has rigorous human efficacy data.
Is BPC-157 safe?: Short-term tolerability appears favorable in animals and the few small human reports, with no lethal dose identified in animal toxicology. However, long-term human safety is unstudied, a theoretical concern exists around promoting angiogenesis in the setting of cancer, and unregulated product quality is a real risk. It is not recommended for human use.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.